Evidence Hub

Phenolic-derived compounds in osteoporosis-Mechanisms, clinical evidence, and drug delivery: A review

Ahmad Hairi H, Jusoh RR, Sadikan MZ, Shuid AN

Biomolecules & biomedicine, 2025

1 citation

Abstract

Osteoporosis is a degenerative skeletal disorder characterized by reduced bone mass and the deterioration of bone microarchitecture, resulting in an increased risk of fractures. Its development is driven by an imbalance in bone remodeling, where osteoclastic bone resorption surpasses osteoblastic bone formation. Factors such as oxidative stress, chronic inflammation, ferroptosis, and hormonal changes, particularly estrogen deficiency in postmenopausal women, contribute to this imbalance. Metabolites derived from phenolic compounds have emerged as promising natural agents for osteoporosis prevention due to their antioxidant, anti-inflammatory, and hormone-modulating properties. Key phenolic groups, including flavonoids (quercetin), isoflavones (genistein and daidzein), and stilbenes (resveratrol), have demonstrated significant osteoprotective effects by regulating receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin (OPG) signaling, activating Wnt and β-catenin pathways, and suppressing inflammatory cytokines. Clinical findings indicate that these compounds may enhance bone mineral density and modulate bone turnover markers in populations at risk for osteoporosis. However, their clinical application is limited by low bioavailability and rapid metabolism. Advances in drug delivery systems, including nanoencapsulation, liposomal formulations, and prodrug design, have improved stability, absorption, and targeted delivery to bone, thereby enhancing…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free